Financiado en parte por Pronova BioPharma Norge
Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease
Musa-Veloso K, Venditti C, Lee HY, Darch M, Floyd S, West S, Simon R
Nutrition reviews · 88 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Pronova BioPharma Norge
Según 1 financiador declarado.
Publicación
- Publicado
- 2018-04-10 · Nutr Rev · vol. 76 · número 8 · págs. 581–602
- Editorial
- Oxford University Press
- Citado
- 123 citas · más que el 88% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 78 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Aquaculture Nutrition and Growth
- Palabras clave
- non-alcoholic fatty liver disease, n-3 long-chain polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, dietary supplementation, nonalcoholic steatohepatitis, liver fat, steatosis, liver enzymes, metabolic risk factors, pediatric patients
- MeSH
- liver, humans, dietary fats, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, treatment outcome, dietary supplements, adult, middle aged, female, male, clinical trials as topic, non-alcoholic fatty liver disease
7 autores
- Kathy Musa‐Veloso🇨🇦 · autor de correspondenciaIntertek (Canada)
- Carolina C. Venditti🇨🇦Intertek (Canada)
- Han Youl Lee🇨🇦Intertek (Canada)
- Maryse Darch🇨🇦Intertek (Canada)
- Seth Floyd🇨🇦Intertek (Canada)
- Spencer West🇨🇦Intertek (Canada)
- Ryan R. Simon🇨🇦Intertek (Canada)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Treatment options for nonalcoholic fatty liver disease (NAFLD) are needed.
Objective
The aim of this review was to systematically assess the effects of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs), particularly eicosapentaenoic acid and docosahexaenoic acid, on liver-related and metabolic outcomes in adult and pediatric patients with NAFLD.
Data sources
The online information service ProQuest Dialog was used to search 8 literature databases.
Study selection
Controlled intervention studies in which the independent effects of n-3 LC-PUFAs could be isolated were eligible for inclusion.
Data extraction
The 18 unique studies that met the criteria for inclusion were divided into 2 sets, and data transcriptions and study quality assessments were conducted in duplicate. Each effect size was expressed as the weighted mean difference and 95%CI, using a random-effects model and the inverse of the variance as a weighting factor.
Results
Based on the meta-analyses, supplementation with n-3 LC-PUFAs resulted in statistically significant improvements in 6 of 13 metabolic risk factors, in levels of 2 of 3 liver enzymes, in liver fat content (assessed via magnetic resonance imaging/spectroscopy), and in steatosis score (assessed via ultrasonography). Histological measures of disease [which were assessed only in patients with nonalcoholic steatohepatitis (NASH)] were unaffected by n-3 LC-PUFA supplementation.
Conclusions
Omega-3 LC-PUFAs are useful in the dietary management of patients with NAFLD. Additional trials are needed to better understand the effects of n-3 LC-PUFAs on histological outcomes in patients with NASH.
Systematic review registration
PROSPERO CRD42017055951.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.